Volume | 29,550 |
|
|||||
News | - | ||||||
Day High | 13.425 | Low High |
|||||
Day Low | 12.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Assembly Biosciences Inc | ASMB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
13.34 | 12.00 | 13.425 | 12.65 | 13.36 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
306 | 29,550 | US$ 12.73 | US$ 376,268 | - | 7.692 - 20.04 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:20:35 | formt | 150 | US$ 12.70 | USD |
Assembly Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
67.93M | 5.48M | - | 7.16M | -61.23M | -11.17 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Assembly Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ASMB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.36 | 13.90 | 12.00 | 13.34 | 8,802 | -0.66 | -4.94% |
1 Month | 13.30 | 15.19 | 12.00 | 13.86 | 17,747 | -0.60 | -4.51% |
3 Months | 11.6412 | 15.19 | 9.84 | 12.09 | 96,046 | 1.06 | 9.10% |
6 Months | 10.152 | 15.19 | 7.692 | 9.87 | 329,270 | 2.55 | 25.10% |
1 Year | 11.5248 | 20.04 | 7.692 | 12.88 | 603,198 | 1.18 | 10.20% |
3 Years | 52.08 | 56.28 | 7.692 | 25.84 | 585,944 | -39.38 | -75.61% |
5 Years | 188.40 | 348.00 | 7.692 | 65.40 | 581,009 | -175.70 | -93.26% |
Assembly Biosciences Description
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. |